FB301 for Vaginal Dysbiosis

This trial explores a treatment called FB301, a potential new drug, for women who have experienced a failed frozen embryo transfer (FET) and have a specific bacterial imbalance in the vagina, known as dysbiosis. Researchers aim to determine if taking FB301 during a mock FET cycle can improve the balance of vaginal bacteria, potentially enhancing future pregnancy chances. Participants will take either FB301 or a placebo after a vaginal cleansing and provide samples during several clinic visits. Women with regular menstrual periods who have had one unsuccessful FET, not due to male factors or blocked fallopian tubes, may be suitable for this trial. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial does not specify if you need to stop taking your current medications. However, if you are taking medications that suppress the immune system or require regular antibiotics, you may not be eligible to participate.

Previous studies have shown that FB301 is well-tolerated. Research indicates no serious side effects have been linked to probiotic products like FB301, suggesting the treatment is generally safe.

Regarding chlorhexidine, sometimes used with FB301, data shows it is mostly well-tolerated. Most people report no vaginal irritation, with only a few experiencing mild or moderate irritation. This indicates that using FB301 with chlorhexidine is safe for most people.

Unlike the standard treatments for vaginal dysbiosis, which often include antibiotics or antifungal medications, FB301 stands out due to its novel approach. Researchers are excited about FB301 because it uses a unique probiotic formulation that aims to restore the natural balance of bacteria in the vagina, rather than just eliminating harmful bacteria. This could potentially lead to fewer side effects and a more sustainable long-term solution for maintaining vaginal health. Moreover, the dual combination with Chlorhexidine in one experimental arm might enhance its effectiveness by providing an initial cleansing action followed by probiotic support. This innovative method offers a promising shift in addressing the root cause of dysbiosis rather than merely managing symptoms.

Studies have shown that FB301 may help restore the natural balance of bacteria in women with vaginal dysbiosis, an imbalance of bacteria in the vagina. In this trial, participants may receive FB301 with chlorhexidine, a germ-killing solution that research indicates effectively reduces harmful vaginal bacteria. In trials, over 90% of women treated with a chlorhexidine-based solution showed improvement. This suggests that FB301 might help create a healthier bacterial environment, potentially improving pregnancy outcomes.¹²³⁵⁶